PMM.88 Screening for Down’s Syndrome in Women with Renal Disease

    loading  Checking for direct PDF access through Ovid

Abstract

Introduction

In 2001, the UK National Screening Committee advised that all pregnant mothers should be offered a screening test for Down’s syndrome (DS). This is performed at first (biomarkers and ultrasound) or second trimester (biochemical screen).

Introduction

There are limited data reporting pregnant women with chronic kidney disease (CKD) have higher false positive screening rates possibly because of reduced clearance of β-hCG (1–3). Our aim was to establish whether standard DS screening is appropriate in pregnant women with renal disease.

Methods

We performed a retrospective, single centre review of DS screening data for women attending a tertiary renal-antenatal clinic over the past 5 years and correlated with clinical outcome.

Results

A total of 240 women had renal function checked at the time of screening. Twenty-seven% had creatinine ≥60 µmol/L-above upper normal pregnancy value (range 24–544). There were a higher proportion of positive screens compared to the general population at first (5.7% vs 2%) and second trimester (9% vs 3.5%). No patient had a baby affected with DS. Increased creatinine was associated with higher levels of unconjugated oestriol (uE3), free and total β-hCG (p ≤ 0.01) and a higher DS risk score (p ≤ 0.01). Increased proteinuria also correlated with a higher β-hCG (p ≤ 0.01) and risk score (p ≤ 0.02). In patients with a high risk score; 30% had IUGR, 10% pre-term delivery and 56% delivered a small baby.

Conclusion

Renal function appears to affect levels of β-hCG and uE3and also independently influence the risk score in DS screening. Alternative screening may need to be considered in this group or renal impairment corrected for.

Related Topics

    loading  Loading Related Articles